Category: Research

Interview with Datavant’s Bob Borek and Jason LaBonte

published date
September 15th, 2021 by

Jason LaBonte
Jason LaBonte
Bob Borek
Bob Borek

Datavant is fostering an ecosystem of healthcare data to facilitate secure exchange of information and analytics that improve patient care. The company recently made headlines through a $7 Billion merger with Ciox, uniting Datavant’s world of de-identified data with Ciox’s domain expertise in patient identified records.

In this episode of the HealthBiz podcast, Datavant’s Chief Strategy Officer Jason LaBonte and Chief Operating Officer Bob Borek discuss the evolution of healthcare data, the Ciox merger, how the company has fared during the pandemic, and their long term vision.

Jason is reading Project Hail Mary by Andy Weir –whose fiction appeals to Jason’s training as a PhD scientist– and Bob likes Cadillac Desert by Marc Reisner about the history of water rights in the West.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle PodcastsYouTube and  many more services. Please consider rating the podcast on Apple Podcasts.


By healthcare business consultant David E. Williams, president of Health Business Group.

Interview with StimLabs CEO John Daniel

published date
September 8th, 2021 by

johndaniel
StimLabs CEO John Daniel

StimLabs CEO John Daniel started out as a US Marine and then rode on a beer truck. But, while in school he sat next to someone who told him about CryoLife where he started in an entry level role as a lab technician. He’s spent his whole career in regenerative medicine, authored 30 patents and now runs StimLabs, which develops and produces regenerative medicine products.

One of John’s favorite books is Leaders Eat Last by Simon Sinek, which teaches and reinforces principles John learned in the Corps.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle PodcastsYouTube and  many more services. Please consider rating the podcast on Apple Podcasts.


By healthcare business consultant David E. Williams, president of Health Business Group.

Interview with CytImmune CEO Saba Malak

published date
June 17th, 2021 by

Saba Malak photo
CytImmune CEO Saba Malak

I first encountered Saba Malak when I was a summer consultant at Boston Consulting Group and he was a new MBA. We stayed in touch and when I became chairman of Advanced Practice Strategies a few years later, Saba joined the board as lead investor.

Since then, Saba has invested in various healthcare and biotech companies in the public and private markets. I never thought of Saba as an operating executive –and apparently neither did he– but a couple of years ago he became so enamored with a company he’d invested in that he decided to take the plunge and become CEO.

That company, CytImmune is establishing a global leadership role in the field of cancer nanomedicine. It is a platform company with products of its own in development. The potential is huge, and in this episode of the HealthBiz podcast Saba explains the technology and why he is confident it will ultimately help patients. The company has a Phase II development collaboration with the National Cancer Institute, and is scaling up its manufacturing to be ready.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle PodcastsYouTube and  many more services. Please consider rating the podcast on Apple Podcasts.


By healthcare business consultant David E. Williams, president of Health Business Group.

What’s next for healthcare as Dems take the Senate?

published date
January 6th, 2021 by

It’s a momentous week in Georgia, Washington and these United States. In this special episode of the HealthBiz podcast, Bloomberg Intelligence Analyst, Brian Rye and I discuss the health policy implications of the likely 50+1 Democratic Senate majority. Listen in as we discuss drug pricing, Medicare Advantage, and the public option.

The HealthBiz podcast is available on SpotifyApple PodcastsGoogle Podcasts and  many more services. Please consider rating the podcast on Apple Podcasts. Doing so helps the podcast reach more listeners.

Check out the rough (AI generated) transcript.


By healthcare business consultant David E. Williams, president of Health Business Group.

ICER founder Dr. Steve Pearson explains COVID-19 remdesivir pricing model

published date
November 12th, 2020 by

Steve scaled e1603726353244
Dr. Steve Pearson

Drug pricing is the hottest topic in healthcare, and ICER founder Dr. Steve Pearson is the coolest person to discuss it with.

In this episode of the HealthBiz podcast, Steve describes how the Institute for Clinical and Economic Review (ICER) compiles and analyzes clinical evidence to estimate the fair value of treatments for cancer and other serious illnesses. ICER has been especially active during the pandemic, developing a pricing model for remdesivir and other COVID-19 therapies that’s being used in the United States and by health technology assessment agencies around the world.

For fun, he has been reading Paradise Lost by John Milton.

This is the second episode I’ve recorded on COVID-19 drug pricing. Check out the first one: Remdesivir powers activate! with Dr. Surya Singh.

The HealthBiz podcast is now on SpotifyApple PodcastsGoogle Podcasts and  many more services, making it easy to subscribe.

Below is a rough (AI-generated) transcript of the episode.



—–

By healthcare business consultant David E. Williams, president of Health Business Group